Publication Q&A: Targeting a Site of Vulnerability to Inhibit Plasmodium vivax Malaria

Ganesh R.R. Visweswaran, PhD, research scientist IV in the Kaushansky Lab at Seattle Children's, shares insights from his research.

Is this research a first in any way?

Yes, the identified neutralizing epitopes and the monoclonal antibody binding to one of the epitopes are novel. We have a patent application covering part of this work.  

What was the need for this research?

Despite the global burden of malaria, there is currently no approved vaccine against Plasmodium vivax, a widespread human malaria parasite that can remain dormant in the liver and cause repeated infections. Therefore, identifying new protective targets is essential for developing an effective vaccine that prevents P. vivax infection and reduces disease transmission. Such a vaccine could help protect vulnerable populations, particularly pregnant women and children under five living in malaria-endemic regions, while also benefiting American travelers, tourists and military personnel who may be exposed to malaria during overseas travel or deployment. 

How can this research lead to better ways to treat/prevent/diagnose? What is the potential impact?

This research provides a foundation for developing more effective vaccines against Plasmodium vivax malaria, for which no approved vaccine currently exists. By identifying new protective regions (epitopes) on the parasite's circumsporozoite protein (PvCSP) and demonstrating that antibodies targeting these regions can block parasite infection of liver cells, our findings offer promising new targets for vaccine development. Furthermore, understanding how these antibodies recognize and neutralize the parasite at the molecular level can guide the design of improved vaccines that generate stronger protective immune responses. Ultimately, this research could help prevent initial infections, reduce the establishment of dormant liver-stage parasites that cause relapses and limit malaria transmission, contributing to global malaria elimination efforts. 

What are the next steps and long-term goals for this research?

The next steps are to use our findings to design and evaluate improved Plasmodium vivax vaccines that target the newly identified protective epitopes on the circumsporozoite protein (PvCSP). We aim to determine whether vaccines incorporating these epitopes can generate strong neutralizing antibody responses and prevent parasite infection in preclinical models. We also plan to investigate how antibodies targeting different regions of PvCSP work together to enhance protection. Our long-term goal is to develop a safe, effective and broadly protective vaccine against P. vivax malaria that can prevent liver-stage infection, reduce relapses and contribute to global malaria elimination efforts. 

How can the scientific community and industry partners collaborate on this work?

We invite researchers, vaccine developers and industry partners to collaborate with us in translating our discovery of novel protective epitopes on Plasmodium vivax circumsporozoite protein (PvCSP) into next-generation malaria vaccines. By combining expertise in antibody discovery, structural biology, vaccine design and preclinical evaluation, we can accelerate the development of effective vaccines that prevent P. vivax infection and reduce malaria transmission, ultimately contributing to global malaria elimination efforts. 

Related Categories

• Infectious Diseases
• Malaria